Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis
Table 3
Results of univariate and multivariate analyses.
Characteristic
Patients (N)
Median PFS (months)
Univariate P value
Multivariate value
Median OS (months)
Univariate P value
Multivariate value
Age group
<70 years
542
11.3
0.28
—
25.0
0.17
—
≥70 years
66
10.1
23.1
Gender
Male
368
10.6
0.58
—
23.9
0.39
—
Female
240
11.5
25.8
KPS
90–100
442
12.3
0.001
0.002
27.4
0.0003
0.004
70–80
166
9.2
21.6
Histology
SCC
326
10.7
0.92
—
23.8
0.72
—
AC
282
11.1
24.9
T-stage
1–2
254
13.2
<0.001
<0.001
28.7
<0.001
<0.001
3–4
354
9.9
21.8
N-stage
2
317
13.2
<0.001
<0.001
29.3
<0.001
<0.001
3
291
9.6
20.2
Stage
IIIB
369
13.4
<0.001
<0.001
29.6
<0.001
<0.001
IIIC
239
9.6
21.9
SIRI
<1.9
304
14.2
<0.001
<0.001
30.3
<0.001
<0.001
≥1.9
304
9.0
21.3
SIRI group
1
171
15.0
<0.001
<0.001
36.7
<0.001
<0.001
2
345
11.1
23.9
3
92
7.1
13.8
Note. SIRI groups: SIRI-1, stage IIIB and SIRI < 1.9; SIRI-2, stage IIIB and SIRI ≥ 1.9 or stage IIIC and SIRI < 1.9; SIRI-3, stage IIIC and SIRI ≥ 1.9. Abbreviations. PFS: progression-free survival; OS: overall survival; KPS: Karnofsky performance score; SCC: squamous cell carcinoma; AC: adenocarcinoma; T: tumor; N: node; SIRI: systemic inflammation response index.
